drugset / Trial / NCT01809743

Regadenoson and Adenosine

NCT01809743

Phase 3 Completed 100 enrolled Lokien van Nunen
RandomizedParallel-groupOpen-labelDiagnostic

Summary

The aim of the study is to test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the gold standard)and to investigate the time intervals of maximum hyperemia induced by centrally and peripherally administered Regadenoson.

Timeline

Start
2013-01
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adenosine Small molecule 140 ug/kg Intravenous
Comparator Regadenoson Diagnostic / imaging agent 400 ug Intravenous